Fairmount Funds Management LLC - May 23, 2024 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
Director
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Stock symbol
DNTH
Transactions as of
May 23, 2024
Transactions value $
$0
Form type
4
Date filed
5/28/2024, 07:57 PM
Previous filing
May 16, 2024
Next filing
Jun 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +11K $0.00 11K May 23, 2024 Common Stock 11K $21.77 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to Tomas Kiselak's continued service to the Issuer through the vesting date.
F2 Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therin.

Remarks:

Fairmount may be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.